HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology21 papers

Hypertrophy of submandibular gland

Last edited: 4/23/2026

Overview

Submandibular gland hypertrophy involves abnormal enlargement of the submandibular salivary gland, often mediated by adrenergic beta-1 receptor activation as evidenced in animal models 1.

Diagnosis

  • Elevated glandular protein and nucleic acid content 1
  • Increased RNA/DNA ratio indicative of cellular proliferation 1
  • Imaging studies (e.g., ultrasound, MRI) to assess gland size and morphology 1

    • Management

  • Beta-1 receptor antagonists like metoprolol may inhibit glandular enlargement 1
  • Specific dosing not established in clinical guidelines based on current abstract 1

    • Special Populations

  • No specific data provided for pregnancy, pediatrics, elderly, or comorbidities 1

    • Key Recommendations

  • Consider beta-1 receptor antagonists such as metoprolol for inhibiting submandibular gland hypertrophy based on preclinical evidence 1 (Evidence: Moderate)
  • Further clinical trials are needed to establish dosing and efficacy in humans 1 (Evidence: Expert opinion)

    • References

    1 Brenner GM, Wulf RG. Adrenergic beta receptors mediating submandibular salivary gland hypertrophy in the rat. The Journal of pharmacology and experimental therapeutics 1981. link

    Original source

    1. [1]
      Adrenergic beta receptors mediating submandibular salivary gland hypertrophy in the rat. — Brenner GM, Wulf RG The Journal of pharmacology and experimental therapeutics (1981)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG